These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Evaluation of the toxicity of glucocorticoids in patients with autoimmune blistering disease using the Glucocorticoid Toxicity Index: A cohort study. Liang Y; Zeng FAP; Sheriff T; Wilson A; Bilgic A; Feng G; Stone JH; Murrell DF JAAD Int; 2022 Mar; 6():68-76. PubMed ID: 35059661 [TBL] [Abstract][Full Text] [Related]
5. The Glucocorticoid Toxicity Index-Metabolic Domains, an abridged version of the Glucocorticoid Toxicity Index: post-hoc analysis of data from the ADVOCATE trial. Patel NJ; Jayne DRW; Merkel PA; Bekker P; Zhang Y; McDowell PJ; Johal J; Heaney LG; Murrell D; Stone MN; Yue H; Stone JH Lancet Rheumatol; 2023 Jul; 5(7):e413-e421. PubMed ID: 38251552 [TBL] [Abstract][Full Text] [Related]
6. The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study. McDowell PJ; Diver S; Yang F; Borg C; Busby J; Brown V; Shrimanker R; Cox C; Brightling CE; Chaudhuri R; Pavord ID; Heaney LG; Lancet Respir Med; 2021 Oct; 9(10):1174-1184. PubMed ID: 33971168 [TBL] [Abstract][Full Text] [Related]
7. Mepolizumab add-on therapy in a real world cohort of patients with severe eosinophilic asthma: response rate, effectiveness, and safety. van Toor JJ; van der Mark SC; Kappen JH; In 't Veen JCCM; Braunstahl GJ J Asthma; 2021 May; 58(5):651-658. PubMed ID: 31999203 [No Abstract] [Full Text] [Related]
8. Glucocorticoid Toxicity Index scores by domain in patients with antineutrophil cytoplasmic antibody-associated vasculitis treated with avacopan versus standard prednisone taper: post-hoc analysis of data from the ADVOCATE trial. Patel NJ; Jayne DRW; Merkel PA; Bekker P; Zhang Y; Yue H; Stone JH Lancet Rheumatol; 2023 Mar; 5(3):e130-e138. PubMed ID: 38251609 [TBL] [Abstract][Full Text] [Related]
9. Anti-IL5 therapies for asthma. Farne HA; Wilson A; Powell C; Bax L; Milan SJ Cochrane Database Syst Rev; 2017 Sep; 9(9):CD010834. PubMed ID: 28933516 [TBL] [Abstract][Full Text] [Related]
10. Estimating glucocorticoid-related morbidity in lupus nephritis using the glucocorticoid toxicity index. Usiskin IM; Kyttaris VC Lupus; 2023 Apr; 32(4):565-570. PubMed ID: 36825983 [TBL] [Abstract][Full Text] [Related]
11. Adherence to corticosteroids and clinical outcomes in mepolizumab therapy for severe asthma. d'Ancona G; Kavanagh J; Roxas C; Green L; Fernandes M; Thomson L; Dhariwal J; Nanzer AM; Jackson DJ; Kent BD Eur Respir J; 2020 May; 55(5):. PubMed ID: 32060061 [TBL] [Abstract][Full Text] [Related]
12. Mepolizumab treatment in patients with severe eosinophilic asthma. Ortega HG; Liu MC; Pavord ID; Brusselle GG; FitzGerald JM; Chetta A; Humbert M; Katz LE; Keene ON; Yancey SW; Chanez P; N Engl J Med; 2014 Sep; 371(13):1198-207. PubMed ID: 25199059 [TBL] [Abstract][Full Text] [Related]
13. Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis. Harrison T; Canonica GW; Chupp G; Lee J; Schleich F; Welte T; Valero A; Gemzoe K; Maxwell A; Joksaite S; Yang S; Howarth P; Van Dyke MK Eur Respir J; 2020 Oct; 56(4):. PubMed ID: 32817259 [TBL] [Abstract][Full Text] [Related]
14. Mepolizumab and Oral Corticosteroid Stewardship: Data from the Australian Mepolizumab Registry. Thomas D; Harvey ES; McDonald VM; Stevens S; Upham JW; Katelaris CH; Kritikos V; Gillman A; Harrington J; Hew M; Bardin P; Peters M; Reynolds PN; Langton D; Baraket M; Bowden JJ; Bowler S; Chien J; Chung LP; Farah CS; Grainge C; Jenkins C; Katsoulotos GP; Lee J; Radhakrishna N; Reddel HK; Rimmer J; Sivakumaran P; Wark PAB; Gibson PG J Allergy Clin Immunol Pract; 2021 Jul; 9(7):2715-2724.e5. PubMed ID: 33545399 [TBL] [Abstract][Full Text] [Related]
15. Bronchial thermoplasty versus mepolizumab: Comparison of outcomes in a severe asthma clinic. Langton D; Sha J; Guo S; Sharp J; Banks C; Wang W; Plummer V; Thien F Respirology; 2020 Dec; 25(12):1243-1249. PubMed ID: 32365431 [TBL] [Abstract][Full Text] [Related]
16. Mepolizumab in Severe Eosinophilic Asthma: A 2-Year Follow-Up in Specialized Asthma Clinics in Greece: An Interim Analysis. Kallieri M; Zervas E; Katsoulis K; Fouka E; Porpodis K; Samitas K; Papaioannou AI; Kipourou M; Gaki E; Vittorakis S; Markatos M; Dimakou K; Ampelioti S; Koukidou S; Makris M; Ntakoula M; Mitrova MH; Glynos K; Antoniou KM; Gaga M; Tzanakis N; Markopoulou K; Papakosta D; Bakakos P; Loukides S Int Arch Allergy Immunol; 2020; 181(8):613-617. PubMed ID: 32570256 [TBL] [Abstract][Full Text] [Related]
17. Real-World Effectiveness and the Characteristics of a "Super-Responder" to Mepolizumab in Severe Eosinophilic Asthma. Kavanagh JE; d'Ancona G; Elstad M; Green L; Fernandes M; Thomson L; Roxas C; Dhariwal J; Nanzer AM; Kent BD; Jackson DJ Chest; 2020 Aug; 158(2):491-500. PubMed ID: 32275980 [TBL] [Abstract][Full Text] [Related]